Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
SJR0.254
US
USJournal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | — | — | 0.254 | Q4 | 37.3% | |
| 2024 | — | — | 0.310 | Q4 | 46.7% | |
| 2023 | — | — | 0.419 | Q3 | 59.2% | |
| 2022 | — | — | 0.333 | Q4 | 53.8% | |
| 2021 | — | — | 0.268 | Q4 | 47.9% | |
| 2020 | — | — | 0.309 | Q4 | 51.4% | |
| 2019 | — | — | 0.583 | Q3 | 71.8% | |
| 2018 | — | — | 0.505 | Q3 | 65.6% | |
Impact history
Annual SJR and Impact Factor trend.
SJR
Journal record
ISSN
2167-9436
country
UScoverage
2013-2025